All In Biotech

Drug Trial Radar · NCT06671938

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients With Mild to Moderate Parkinson's Disease on Stable Symptomatic Parkinson's Disease Medication and in Patients With Multiple System Atrophy

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Oct 24, 2024

Primary completion

Aug 10, 2026

Study completion Aug 10, 2026

Sponsor

Lead sponsor
BioArctic ABIndustry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.

Conditions

  • Parkinson Disease
  • Multiple System Atrophy

Interventions

  • exidavnemabDrug

    The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)

  • Placebo ComparatorDrug

    The trial medication will be administered as an intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs).Time frame: From first dose to Day 176

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Centrum Medyczyne Neuromed Sp. z o.o.

    Bydgoszcz, Poland

  • Krakowska Akademia Neurologii Sp. Z o.o

    Krakow, Poland

  • Policlínica Gipuzkoa

    San Sebastián, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Andalusia, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, Spain

  • Hospital Universitari General de Catalunya

    Sant Cugat del Vallès, Barcelona, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.